| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS10009167 | HBV | ENSG00000183873.20 | protein_coding | SCN5A | No | No | 6331 | E9PG18 E9PHB6 H9KVD2 K4DIA1 Q14524 Q86V90 |
| TVIS20012030 | HPV | ENSG00000183873.20 | protein_coding | SCN5A | No | No | 6331 | E9PG18 E9PHB6 H9KVD2 K4DIA1 Q14524 Q86V90 |
| TVIS20036049 | HPV | ENSG00000183873.20 | protein_coding | SCN5A | No | No | 6331 | E9PG18 E9PHB6 H9KVD2 K4DIA1 Q14524 Q86V90 |
| TVIS20056806 | HPV | ENSG00000183873.20 | protein_coding | SCN5A | No | No | 6331 | E9PG18 E9PHB6 H9KVD2 K4DIA1 Q14524 Q86V90 |
| TVIS44025067 | HTLV-1 | ENSG00000183873.20 | protein_coding | SCN5A | No | No | 6331 | E9PG18 E9PHB6 H9KVD2 K4DIA1 Q14524 Q86V90 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | SCN5A |
|---|---|
| DrugBank ID | DB01195 |
| Drug Name | Flecainide |
| Target ID | BE0000197 |
| UniProt ID | Q14524 |
| Regulation Type | inhibitor |
| PubMed IDs | 10617684; 10758053; 10961955; 11307783; 11535580; 15272045; 11196553; 12601084; 11752352 |
| Citations | Nagatomo T, January CT, Makielski JC: Preferential block of late sodium current in the LQT3 DeltaKPQ mutant by the class I(C) antiarrhythmic flecainide. Mol Pharmacol. 2000 Jan;57(1):101-7.@@Benhorin J, Taub R, Goldmit M, Kerem B, Kass RS, Windman I, Medina A: Effects of flecainide in patients with new SCN5A mutation: mutation-specific therapy for long-QT syndrome? Circulation. 2000 Apr 11;101(14):1698-706.@@Priori SG, Napolitano C, Schwartz PJ, Bloise R, Crotti L, Ronchetti E: The elusive link between LQT3 and Brugada syndrome: the role of flecainide challenge. Circulation. 2000 Aug 29;102(9):945-7.@@Cerrone M, Crotti L, Faggiano G, De Michelis V, Napolitano C, Schwartz PJ, Priori SG: [Long QT syndrome and Brugada syndrome: 2 aspects of the same disease?]. Ital Heart J Suppl. 2001 Mar;2(3):253-7.@@Viswanathan PC, Bezzina CR, George AL Jr, Roden DM, Wilde AA, Balser JR: Gating-dependent mechanisms for flecainide action in SCN5A-linked arrhythmia syndromes. Circulation. 2001 Sep 4;104(10):1200-5.@@Ramos E, O'leary ME: State-dependent trapping of flecainide in the cardiac sodium channel. J Physiol. 2004 Oct 1;560(Pt 1):37-49. Epub 2004 Jul 22.@@Shimizu W, Antzelevitch C, Suyama K, Kurita T, Taguchi A, Aihara N, Takaki H, Sunagawa K, Kamakura S: Effect of sodium channel blockers on ST segment, QRS duration, and corrected QT interval in patients with Brugada syndrome. J Cardiovasc Electrophysiol. 2000 Dec;11(12):1320-9.@@Liu H, Atkins J, Kass RS: Common molecular determinants of flecainide and lidocaine block of heart Na+ channels: evidence from experiments with neutral and quaternary flecainide analogues. J Gen Physiol. 2003 Mar;121(3):199-214.@@Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. |
| Groups | Approved; Withdrawn |
| Direct Classification | Benzamides |
| SMILES | FC(F)(F)COC1=CC(C(=O)NCC2CCCCN2)=C(OCC(F)(F)F)C=C1 |
| Pathways | Flecainide Action Pathway |
| PharmGKB | PA449646 |
| ChEMBL | CHEMBL652 |
